Organon Investor Presentation — October 2022

Document content

Q3 2022 Earnings OrganonDisclaimer statement

Safe Harbor for Forward-Looking Statements

Except for historical information herein, this presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the

U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future

financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,”

“believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the

company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties

materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited

to, an inability to execute on our business development strategy or realize the benefits of our planned acquisitions; general economic factors, including

interest rate and currency exchange rate fluctuations; general industry conditions and competition; the impact of the ongoing COVID-19 pandemic and

emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global

trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new

product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the

company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and

sovereign risk; difficulties developing and sustaining relationships with commercial counterparties; dependence on the effectiveness of the company’s

patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company

undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional

factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the

Securities and Exchange Commission (SEC), including the company's Annual Report on Form 10-K for the year ended December 31, 2021 and

subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).This text should be viewed in conjunction with Organon’s Q3 2022 earnings call